✨ Free AI Report
FamiCord AG (formerly VITA 34 AG): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research FamiCord AG (formerly VITA 34 AG)
Company Research

FamiCord AG (formerly VITA 34 AG): Business Overview, Financials & Competitive Analysis

FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. The company operates in the medical technology sector as a cell bank/stem...

Analyst-debate audio for FamiCord AG (formerly VITA 34 AG)

AskCyborg analysts argue the bull and bear cases for FamiCord AG (formerly VITA 34 AG) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
7/ 10Solid

Cyborg Score thesis

European cell banking leader with recurring revenue model, diversifying into higher-value cell therapies while navigating...

Read the full analyst-debate transcript →
Industry Medical Technology / Cell Banking & Regenerative Medicine
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest FamiCord AG (formerly VITA 34 AG) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

FamiCord AG (formerly VITA 34 AG) Overview

Pro stress-test →

FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. The company operates in the medical technology sector as a cell bank/stem bank involved in the long-term storage and processing of stem cells from human umbilical cord blood. With over 1 million stored biological material units, the company serves families globally seeking long-term preservation of regenerative cell therapies.

Strategic Profile

Pro stress-test →

The company completed group-wide integration projects following the merger of Vita 34 and PBKM subgroups and recently rebranded to FamiCord AG to strengthen international brand presence. The company is active in the areas of Cell & Gene therapies and CDMO (contract development and manufacturing organization). The strategic positioning emphasizes European market dominance with controlled expansion into adjacent cell therapy applications.

Competitive Landscape

Pro stress-test →

FamiCord is the leading cell bank in Europe and the third largest worldwide. The company competes in the niche but growing private cord blood banking sector against international players and public healthcare systems. Competitive advantages include 25+ years of operational experience, GMP-certified facilities, European market dominance, and expanding services in cell and gene therapies.

Industry Context

FamiCord AG (formerly VITA 34 AG) operates in Medical Technology / Cell Banking & Regenerative Medicine.

Key facts

Founded: 1997 · Headquarters: Leipzig, Germany · Employees: ~100 · Revenue: EUR 82.2M (2024)

What the analysts stress-tested

The top findings that survived the multi-agent debate for FamiCord AG (formerly VITA 34 AG).

  • Customers from about 50 countries have already provided for the health of their families with about one million units of stored biological material at FamiCord.
  • In the 2024 financial year, the company successfully continued its growth trajectory with revenues increasing 6.6% to EUR 82.2 million and EBITDA reaching EUR 8.8 million.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2025FamiCord AG rebranded from VITA 34 AG to strengthen international presence; completed post-merger integration
  • April 20252024 results: EUR 82.2M revenue (+6.6% YoY), EUR 8.8M EBITDA with continued placenta banking expansion
  • +1 moreTrack every material event for FamiCord AG (formerly VITA 34 AG) as it happens. Explore monitoring →
Get alerted when FamiCord AG (formerly VITA 34 AG) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cord Blood BankingEuropean private cord blood banking competitor→Cord Blood BankingGlobal cord blood banking and storage services→Cell Therapy SolutionsPublic cord blood banking networks across Europe→

Compare FamiCord AG (formerly VITA 34 AG) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

FamiCord AG (formerly VITA 34 AG) operates in Medical Technology / Cell Banking & Regenerative Medicine. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Technology / Cell Banking & Regenerative Medicine research →
NEW · MCP server

Ask your AI assistant about FamiCord AG (formerly VITA 34 AG)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare FamiCord AG (formerly VITA 34 AG) and its top competitor on Cyborg Score”
“What did FamiCord AG (formerly VITA 34 AG) do this quarter?”
“Is FamiCord AG (formerly VITA 34 AG) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does FamiCord AG (formerly VITA 34 AG) do?+
FamiCord (formerly Vita 34) was founded in Leipzig in 1997 and today is by far the leading cell bank in Europe and the third largest worldwide. The company operates in the medical technology sector as a cell bank/stem...
What is FamiCord AG (formerly VITA 34 AG)'s Cyborg Score?+
FamiCord AG (formerly VITA 34 AG) has a Cyborg Score of 7/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are FamiCord AG (formerly VITA 34 AG)'s main competitors?+
Named competitors include Cord Blood Banking, Cord Blood Banking, Cell Therapy Solutions. The full competitive landscape is in the AskCyborg report.
How can I get the full FamiCord AG (formerly VITA 34 AG) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the FamiCord AG (formerly VITA 34 AG) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track FamiCord AG (formerly VITA 34 AG) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Medical Technology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Haemonetics Corporation7Optomed Oyj6Siemens Healthineers AG